On 26 August 2022, Guo Guangchang, Chairman of Fosun International, met Gu Hui, Consul-General of the People's Republic of China in Gothenburg, Sweden, accompanied by the Economic and Commercial Office of the Consulate-General. Li Haifeng, Global Partner of Fosun, attended the meeting.Guo Guangchang reported Fosun's businesses in Sweden

29 August 2022 - Forbes China recently released its “2022 China ESG 50” list. Fosun International has been included on the list for its outstanding ESG performance and its active contribution to the fight against the COVID-19 pandemic. Forbes China pointed out that ESG is still in its infancy in China, and the 50 selected companies are all pioneers in the field of ESG.Forbe

Highlights:Revenue forthe first half of 2022amounted toRMB21,340 million, an increase of 25.88% YOY;Net profit (after extraordinary gain or loss) attributable to shareholders of the listed company amounted toRMB1,862 million, an increase of 18.57% YOY; net cash flow from operating activitiesamounted toRMB1,820 million, an increase of 6.66% YOY;Revenue from co

Results HighlightsIn the first half of 2022, the Group's business volume almost doubles. Adjusted EBITDA turned around from negative RMB565 million in the first half of 2021 to RMB1,195 million in the first half of 2022. Loss attributable to equity holders significantly narrowed from RMB2,005 million in the first half of 2021 to RMB197 million in the first half of 2022In the fi

Shanghai, 26 August 2022 – Fosun International Limited (“Fosun International”, stock code: 00656.HK) and HSBC Bank (China) Company Limited (“HSBC China”) renewed a strategic cooperation agreement (the “Agreement”) today to provide strong support for Fosun International and its subsidiaries (“Fosun”) in the aspects of global operation and investment capab

On August 23, the 2022 Fortune China ESG Impact List was announced, with 40 companies on the list.Fosun Pharma topped the list for its remarkable achievements in environmental, social, and corporate governance (ESG) and positive contributions in the fight against the COVID-19 pandemic.The 2022 Fortune China ESG Impact List was produced by the editorial team of

(23August2022) An analyst who is a key opinion leader (KOL) has made an analysis on Bloomberg terminal about Fosun International afterMoody’shas releaseda ratingreportabout the company. The following is the article extracted from the Bloomberg terminal post:The rating agency Moody’s just issued a report today and adjusted the corporate family rating of Fosun International(0656.HK) toB1

On 11 August, Guo Guangchang, Chairman of Fosun International, and his delegation met Zheng Zeguang, Chinese Ambassador to the United Kingdom (UK), at the Chinese Embassy in the UK in London. Bao Ling, Minister for Economic & Commercial Affairs of the Chinese Embassy in the UK, and Fosun's global partners, Li Haifeng, Shi Yu and others attended the meeting.

(25 July 2022) - Shanghai Henlius Biotech, Inc. (2696.HK) announced that the company’s business partner Cipla Limited (“Cipla”) has received the relevant registration certificates from the Therapeutic Goods Administration of Australia (“TGA”) for the approval of Henlius’ self-developed and manufactured HANQUYOU (trastuzumab, trade name in Europe: Zercepac^®) with the specification of 150mg/vial in Australia under the trade names Tuzucip^® and Trastucip^®, covering all indications of the reference trastuzumab approved in Australia. At present, Henlius is working with Cipla in Australia and this approval will help both parties bring HANQUYOU to more patients in Australia.